ganaxolone-neuropsychiatric-disorders.jpg

Dedicated to the
Development of
Ganaxolone

A new mechanism of action designed with selectivity and safety in mind.

 

 

 

icon right treatment

The Right
Treatment

Ganaxolone, a positive allosteric modulator of GABAA, acts on a well-characterized synaptic and extrasynaptic target known for antiepileptic (anti-seizure), anxiolytic (anti-anxiety), and anti-depressive activity.

icon right formulation

The Right
Formulation

Marinus is developing convenient forms of ganaxolone – IV and oral – to maximize the therapeutic reach to adult and pediatric patients in both acute and chronic care settings.

icon cdkl5 deficiency disorder

A Wide Range
of Conditions

Marinus has initiated pivotal studies with ganaxolone in children with rare, CDKL5 deficiency disorderPCDH19-Related Epilepsy and is currently conducting studies in refractory status epilepticus.